• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Bon Natural Life Limited Announces Effectiveness of Reverse Stock Split

    5/15/25 6:15:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BON alert in real time by email

    XI'AN, China, May 15, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, announced today that it will effect a 1-for-25 reverse stock split ("Reverse Stock Split") of its authorized, issued and outstanding Class A ordinary shares, par value $0.001 per share. The Reverse Stock Split will become effective at 12:01a.m., Eastern Time, on May 19, 2025. At such time, each 25 issued and outstanding Class A ordinary shares will automatically be reclassified into one new Class A ordinary share. Proportional adjustments will be made to outstanding equity awards, warrants and convertible notes, and to the number of shares issued and issuable under the Company's stock incentive plans and certain existing agreements. No fractional shares will be issued in connection with the Reverse Stock Split. All fractional shares will be rounded up. The Reverse Stock Split will affect all Class A holders uniformly and will not alter any stockholder's percentage interest in the Company's equity.

    Bon's Class A ordinary shares will continue to trade on The Nasdaq Capital Market under the existing symbol "BON" and will begin trading on a split-adjusted basis when the market opens on May 19, 2025. The new CUSIP number for the Class A ordinary shares following the Reverse Stock Split will be G14492204.

    The Reverse Stock Split is primarily intended to bring the Company into compliance with the $1.00 minimum bid price requirement in order to maintain its listing on Nasdaq. There is no guarantee the Company will meet the minimum bid price requirement.

    Immediately following the Reverse Split our authorized share capital will increase to 1,000,000,000 Class A ordinary shares, par value $0.025 per share; (ii) 50,000,000 Class B ordinary shares, par value $0.001 per share; and (iii) 50,000,000 preference shares, par value $0.001 per share.

    In addition to the Reverse Split and increase in authorized shares, the conversion rate of the Class B ordinary shares, which are currently convertible to Class A ordinary shares on a one-to-one (1:1) basis, will be convertible to Class A ordinary shares on a one-to-twenty-five (1:25) basis (the "Variation of Class Rights").

    The Reverse Split, Variation of Class Rights, and increase in authorized shares was approved by our shareholders at their April 15, 2025 extraordinary general meeting and was accomplished by way of an amendment to our charter documents filed on April 28, 2025.

    About Bon Natural Life Limited

    BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit http://www.bnlus.com.

    Forward-Looking Statements

    Certain statements in this announcement are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. These forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Therefore, you should not rely on any of these forward-looking statements. These risks and uncertainties include, among others: the completion of the offering, the satisfaction of customary closing conditions related to the offering, the intended use of proceeds from the offering, BON's limited operating history and historical losses; BON's ability to raise additional funding; competition from third parties that are developing or have products for similar uses; BON's ability to obtain, maintain and protect its intellectual property; and BON's expectations regarding its growth, strategy, progress towards its goals. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the U.S. Securities and Exchange Commission.

    Investor Relations Contact:

    Cindy Liu | IR

    Email: [email protected]



    Primary Logo

    Get the next $BON alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BON

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BON
    SEC Filings

    View All

    SEC Form 6-K filed by Bon Natural Life Limited

    6-K - Bon Natural Life Ltd (0001816815) (Filer)

    8/4/25 9:20:22 PM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Bon Natural Life Limited

    6-K - Bon Natural Life Ltd (0001816815) (Filer)

    7/21/25 9:00:10 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Bon Natural Life Limited

    6-K - Bon Natural Life Ltd (0001816815) (Filer)

    7/11/25 12:08:48 PM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    $BON
    Leadership Updates

    Live Leadership Updates

    View All

    Bon Natural Life Limited Appoints Wallace Lee as New Chief Financial Officer

    XIAN, China, April 25, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, is pleased to announce the appointment of Mr. Wallace Lee as Chief Financial Officer (CFO), effective April 17, 2023. Mr. Lee succeeds Zhenchao Li, who stepped down from the role of CFO after a 4-year career with the Company, effective April 17, 2023. "We welcome Wallace Lee into BON's executive leadership team." Commented Richard Hu, "Wallace brings exceptional financial, strategic, and operational experience both from multiple industry sectors and experience as a public c

    4/25/23 8:30:00 AM ET
    $BON
    $SXTC
    $WSG
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Services-Misc. Amusement & Recreation

    Bon Natural Life Limited Announces Change to Board Composition

    XIAN, China, June 30, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced the appointment of Jeffrey Guzy, as a new independent Director to its Board of Directors and as Chair of the Audit Committee, both effective June 28, 2022. Effective June 27, 2022, Mr. Christopher Constable resigned as a director of the Company for personal reasons and stepped down as a member and chairman of the audit committee of the Board. The resignation of Mr. Constable did not result from any dispute or disagreement with the Company or the Board on any matter

    6/30/22 4:30:00 PM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    $BON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BON Announces Reciept of Nasdaq Compliance Letter

    XI'AN, China, Aug. 5, 2025 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or "the Company"), a leading provider of bio-ingredient solutions for the natural health and personal care industries, today announced reciept of compliance notification from the Nasdaq Stock Market LLC. As previously reported on a Form 6-K filed with the U.S. Securities and Exchange Commission on July 11, 2025, Bon Natural Life Limited ( "the Company") received notification from the Nasdaq Hearings Panel (the "Panel") that the Company had regained compliance with Listing Rule 5550(a)(2) (the "Bid Price Rule"). The Panel also advised the Company that it will be subject to a one-year Discretionary Panel M

    8/5/25 9:00:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    BON Launches AI-Powered New Drug Research and Development

    XI'AN, China, July 30, 2025 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or "the Company"), a leading provider of bio-ingredient solutions for the natural health and personal care industries, today announced the official launch of its AI-driven drug research and development (R&D) business. Leveraging its extensive library of natural compounds - many derived from Traditional Chinese Medicine (TCM) - the Company will apply artificial intelligence algorithms to identify high potential lead compounds, marking a significant evolution in its pharmaceutical strategy. A lead compound is a molecule with specific biological activity and a chemical structure that serves as a foundation

    7/30/25 9:00:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    BON Announces $22 Million Distribution Agreement for Weight Loss Products with Beijing Huahai Keyuan Technology Co., Ltd

    XI'AN, China, July 21, 2025 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural health and personal care industries, today announced it has entered into a non-exclusive sales distribution agreement with Beijing Huahai Keyuan Technology Co. Ltd. ("Huahai Keyuan"). The term of the agreement is 36 months with a total contract value of US$22 million. Pursuant to the agreement, Huahai Keyuan will sell and distribute Bon's natural weight loss product line across China and Southeast Asia. What sets BON apart is not only the science behind its formulation but also its exceptional user compliance. By eli

    7/21/25 9:00:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    $BON
    Financials

    Live finance-specific insights

    View All

    Bon Natural Life Limited Announces FY2022 Earnings Release Date and Webcast

    Earnings to be released before market opens on Friday, February 10, 2023 XIAN, China, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its FY2022 earnings release for the fiscal year ended September 30, 2021 before the market open on Friday, February 10, 2023. BON will also host an investor conference call and webcast on the same date, beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, COO Ms. Yingchun Xue and CMO Wenjuan Chen. A replay of the call will also be

    2/7/23 8:30:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    Bon Natural Life Limited Announces 2022 Half-Year Earnings Release Date and Webcast

    Earnings to be released before market opens on Monday, August 1, 2022XIAN, China, July 28, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its half-year earnings release for the reporting period ended March 31, 2022 before the market open on Monday, August 1, 2022. BON will also host an investor conference call and webcast on the same date, beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, COO Ms. Yingchun Xue and CMO Wenjuan Chen. A replay of the call will also be archived o

    7/28/22 4:30:00 PM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    Bon Natural Life Limited Announces FY2021 Earnings Release Date and Webcast

    Earnings to be released before market opens on Monday, January 31, 2022 XI'AN, China, Jan. 28, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its FY2021 earnings release for the fiscal year ended September 30, 2021 before the market open on Monday, January 31, 2022. In observation of Chinese New Year, BON will host an investor conference call and webcast on February 3 beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, CMO Ms. Wenjuan Chen and COO Ms. Yingchun Xue. A replay

    1/28/22 9:00:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care